期刊文献+

降脂通络软胶囊治疗高脂血症(血瘀气滞证)的临床综合评价

Clinical comprehensive evaluation of Jiangzhi Tongluo Soft Capsules for treating hyperlipidemia(syndrome of blood stasis and Qi stagnation)
原文传递
导出
摘要 该研究全面梳理降脂通络软胶囊治疗高脂血症(血瘀气滞证)的现有证据,基于《药品临床证据和价值评估管理指南》标准,结合问卷调查、循证医学证据、药物经济学评价等定性与定量相结合的方法,利用多准则决策分析(MCDA)模型,针对安全性、有效性、经济性、创新性、适宜性、可及性、中医药特色“6+1”维度进行临床证据和临床价值的综合评估。安全性证据充分性和已知风险评价显示,降脂通络软胶囊风险可控,安全性证据充足、结果确定。有效性基于Meta分析结果,降脂通络软胶囊能够显著改善患者甘油三酯水平(RR=-0.25,95%CI[-0.41,-0.10],P=0.001),降脂通络软胶囊vs辛伐他汀片在治疗血脂有效率方面疗效相当(RR=1.11,95%CI[0.96,1.27],P=0.15),降脂通络软胶囊vs脂必妥片在治疗血脂有效率方面疗效相当(RR=1.07,95%CI[0.99,1.16],P=0.10),降脂通络软胶囊vs血脂康胶囊在治疗血脂有效率方面效果更佳(RR=1.44,95%CI[1.17,1.76],P=0.0006);GRADE证据均为C级,综合证据质量和证据价值评价结果,认为该品种有效性证据较充足。通过构建Markov经济模型提示,降脂通络软胶囊vs蒲参胶囊治疗方案更具有经济性,综合增量效应水平和干预方案成本水平,认为该药经济性较好。从3个一级指标,18个二级指标进行创新性评价,认为其创新性证据较充足。该药信息服务齐全,问卷调查显示其对临床医生、护士、药师以及患者适宜,综合评价适宜性证据较充足。药品可及性主要涉及药品价格水平、可获得性和可负担性3个方面,降脂通络软胶囊中标价0.72元/粒,报销后治疗费用占城镇居民可支配收入中位数的0.08%,占农村居民可支配收入中位数的0.31%,可及性证据较充足。基于中医药特色评定原则,降脂通络软胶囊中医药特色较突出。综合“6+1”维度,运用CSC v2.0软件计算得出综合衡量价值为0.69,该药临床综合价值证据较为充分。综上,基于降脂通络软胶囊各维度评价结果与综合评价分数,认为其治疗高脂血症(血瘀气滞证)的临床价值证据较充分。建议进一步发表降脂通络软胶囊治疗高脂血症的高质量循证证据,并在说明书【禁忌】项中添加“孕妇禁用”。 This study provides a systematic review of existing evidence concerning the efficacy of Jiangzhi Tongluo Soft Capsules(JTSC)in treating hyperlipidemia(syndrome of blood stasis and Qi stagnation),following the Guidelines for clinical evidence and value assessment of drugs.The qualitative and quantitative methods were integrated,including questionnaire surveys,evidence-based medicine,and pharmacoeconomic evaluation.Multi-criteria decision analysis(MCDA)model was used for comprehensive assessment of the clinical evidence and value of JTSC for hyperlipidemia in"6+1"dimensions:safety,effectiveness,cost-effectiveness,innovation,suitability,accessibility,and traditional Chinese medicine(TCM)characteristics.The safety evidence was sufficient and the results of the known risk assessment indicated that JTSC was safe and had a sufficient safety profile.Meta-analysis showed that JTSC recovered patients'triglyceride levels(RR=-0.25,95%CI[-0.41,-0.10],P=0.001).JTSC had similar efficacy to simvastatin Tablets(RR=1.11,95%CI[0.96,1.27],P=0.15)and Zhibituo Tablets(RR=1.07,95%CI[0.99,1.16],P=0.10)in restoring blood lipid levels.JTSC outperformed Xuezhikang Capsules in recovering blood lipid levels(RR=1.44,95%CI[1.17,1.76],P=0.0006).According to the Grading of Recommendations Assessment,Development and Evaluation(GRADE)system,the evidence was rated as grade C,and the overall evaluation of the quality and value of the evidence indicated that the effectiveness evidence of this product was fairly sufficient.Markov economic model was established,and the results suggested that JTSC was more economical than Pushen Capsules.Considering the incremental effect and the cost of the intervention scheme,JTSC had good cost effectiveness.The innovation of JTSC was evaluated based on three primary indicators and eighteen secondary indicators,which suggested the evidence of innovation for JTSC was abundant.The information of Chinese patent medicines of JTSC was complete,and the survey results showed that the drug was suitable for clinicians,nurses,pharmacists,and patients.The comprehensive evaluation suggested that JTSC had abundant evidence of suitability.The accessibility of a drug mainly involves the price,availability,and affordability of the drug.The tender price of JTSC was 0.72 yuan/capsule,and the treatment cost after refund accounted for 0.08%of the median household disposable income of urban residents and 0.31%of the median household disposable income of rural residents.The evidence of accessibility was abundant.The TCM characteristics of JTSC were prominent.CSC v2.O was used to calculate the comprehensive evaluation value in the"6+1"dimensions,which yielded a score of 0.69,indicating sufficient evidence for the clinical comprehensive value of this drug.According to the evaluation results of each dimension and the comprehensive evaluation score,it is believed that the clinical value evidence of JTSC in treatment of hyperlipidemia(syndrome of blood stasis and Qi stagnation)is sufficient.It is suggested that high-quality evidence-based research should be carried out on the treatment of hyperlipidemia with JTSC,and contraindications in pregnant women should be added in the section of contraindications of the product instruction.
作者 路振凯 刘福梅 张旭明 王雅星 谢雁鸣 LU Zhen-kai;LIU Fu-mei;ZHANG Xu-ming;WANG Ya-xing;XIE Yan-ming(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处 《中国中药杂志》 CAS CSCD 北大核心 2024年第20期5627-5634,共8页 China Journal of Chinese Materia Medica
基金 国家中医药管理局2021岐黄学者支持项目(国家中医药人教函[2022]6) 谢雁鸣全国名老中医药专家传承工作室建设项目(国家中医药人教函[2022]75)。
关键词 降脂通络软胶囊 高脂血症 血瘀气滞证 临床综合评价 Jiangzhi Tongluo Soft Capsules hyperlipidemia syndrome of blood stasis and Qi stagnation clinical comprehensive evaluation
  • 引文网络
  • 相关文献

参考文献21

二级参考文献332

共引文献481

;
使用帮助 返回顶部